TY - JOUR
T1 - Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors
AU - Chandra, Joya
AU - Miller, Claudia P.
AU - Singh, Melissa M.
AU - Rivera-Del Valle, Nilsa
AU - Manton, Christa A.
PY - 2011
Y1 - 2011
N2 - Histone acetylation is a posttranslational modification that plays a role in regulating gene expression. More recently, other nonhistone proteins have been identified to be acetylated which can regulate their function, stability, localization, or interaction with other molecules. Modulating acetylation with histone deacetylase inhibitors (HDACi) has been validated to have anticancer effects in preclinical and clinical cancer models. This has led to development and approval of the first HDACi, vorinostat, for the treatment of cutaneous T cell lymphoma. However, to date, targeting acetylation with HDACi as a monotherapy has shown modest activity against other cancers. To improve their efficacy, HDACi have been paired with other antitumor agents. Here, we discuss several combination therapies, highlighting various epigenetic drugs, ROS-generating agents, proteasome inhibitors, and DNA-damaging compounds that together may provide a therapeutic advantage over single-agent strategies.
AB - Histone acetylation is a posttranslational modification that plays a role in regulating gene expression. More recently, other nonhistone proteins have been identified to be acetylated which can regulate their function, stability, localization, or interaction with other molecules. Modulating acetylation with histone deacetylase inhibitors (HDACi) has been validated to have anticancer effects in preclinical and clinical cancer models. This has led to development and approval of the first HDACi, vorinostat, for the treatment of cutaneous T cell lymphoma. However, to date, targeting acetylation with HDACi as a monotherapy has shown modest activity against other cancers. To improve their efficacy, HDACi have been paired with other antitumor agents. Here, we discuss several combination therapies, highlighting various epigenetic drugs, ROS-generating agents, proteasome inhibitors, and DNA-damaging compounds that together may provide a therapeutic advantage over single-agent strategies.
UR - http://www.scopus.com/inward/record.url?scp=80052653226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052653226&partnerID=8YFLogxK
U2 - 10.1155/2011/514261
DO - 10.1155/2011/514261
M3 - Review article
C2 - 21765634
AN - SCOPUS:80052653226
SN - 1110-7243
VL - 2011
JO - Journal of Biomedicine and Biotechnology
JF - Journal of Biomedicine and Biotechnology
M1 - 514261
ER -